Literature DB >> 29275861

Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor.

Alexander D Barrow1, Melissa A Edeling1, Vladimir Trifonov2, Jingqin Luo3, Piyush Goyal2, Benjamin Bohl2, Jennifer K Bando1, Albert H Kim4, John Walker2, Mary Andahazy2, Mattia Bugatti5, Laura Melocchi5, William Vermi6, Daved H Fremont1, Sarah Cox2, Marina Cella1, Christian Schmedt2, Marco Colonna7.   

Abstract

Many tumors produce platelet-derived growth factor (PDGF)-DD, which promotes cellular proliferation, epithelial-mesenchymal transition, stromal reaction, and angiogenesis through autocrine and paracrine PDGFRβ signaling. By screening a secretome library, we found that the human immunoreceptor NKp44, encoded by NCR2 and expressed on natural killer (NK) cells and innate lymphoid cells, recognizes PDGF-DD. PDGF-DD engagement of NKp44 triggered NK cell secretion of interferon gamma (IFN)-γ and tumor necrosis factor alpha (TNF-α) that induced tumor cell growth arrest. A distinctive transcriptional signature of PDGF-DD-induced cytokines and the downregulation of tumor cell-cycle genes correlated with NCR2 expression and greater survival in glioblastoma. NKp44 expression in mouse NK cells controlled the dissemination of tumors expressing PDGF-DD more effectively than control mice, an effect enhanced by blockade of the inhibitory receptor CD96 or CpG-oligonucleotide treatment. Thus, while cancer cell production of PDGF-DD supports tumor growth and stromal reaction, it concomitantly activates innate immune responses to tumor expansion.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NK cell; NKp44; PDGF-D; cancer; cell cycle; cytokines; growth factor; immunosurveillance; innate lymphoid cells

Mesh:

Substances:

Year:  2017        PMID: 29275861      PMCID: PMC6684025          DOI: 10.1016/j.cell.2017.11.037

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  82 in total

Review 1.  Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in Immunity.

Authors:  Marco Colonna
Journal:  Immunity       Date:  2018-06-19       Impact factor: 31.745

2.  Tumour immunology: Natural killer cells spy greedy tumours.

Authors:  Yvonne Bordon
Journal:  Nat Rev Immunol       Date:  2018-01-30       Impact factor: 53.106

3.  Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.

Authors:  Kiran Kundu; Susmita Ghosh; Rhitajit Sarkar; Avishay Edri; Michael Brusilovsky; Orly Gershoni-Yahalom; Rami Yossef; Avishai Shemesh; Jean-Charles Soria; Vladimir Lazar; Ben-Zion Joshua; Kerry S Campbell; Moshe Elkabets; Angel Porgador
Journal:  Cancer Immunol Res       Date:  2019-06-04       Impact factor: 11.151

Review 4.  Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options.

Authors:  Chaoying Qin; Meng Huang; Yimin Pan; Yuzhe Li; Wenyong Long; Qing Liu
Journal:  Brain Tumor Pathol       Date:  2021-04-26       Impact factor: 3.298

Review 5.  Innate lymphoid cells: A potential link between microbiota and immune responses against cancer.

Authors:  Santosh K Panda; Marco Colonna
Journal:  Semin Immunol       Date:  2019-03-20       Impact factor: 11.130

Review 6.  Tissue-resident cytotoxic innate lymphoid cells in tumor immunosurveillance.

Authors:  Efstathios G Stamatiades; Ming O Li
Journal:  Semin Immunol       Date:  2019-03-21       Impact factor: 11.130

Review 7.  IL-33 in Tumor Immunity: Nothing to Sneeze At.

Authors:  Donye Dominguez; Yi Zhang; Bin Zhang
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

Review 8.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

9.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

10.  Immune effectors responsible for the elimination of hyperploid cancer cells.

Authors:  Fernando Aranda; Kariman Chaba; Norma Bloy; Pauline Garcia; Chloé Bordenave; Isabelle Martins; Gautier Stoll; Antoine Tesniere; Guido Kroemer; Laura Senovilla
Journal:  Oncoimmunology       Date:  2018-05-21       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.